Search clinical trials for: Experimental: Bif-038 arm, low dose

Total 187 results

Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
Anhui Provincial Hospital

Recruiting

Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer

Safety Issues | Efficacy, Self

China
Pfizer
Trans Tech Pharmaceuticals

Completed

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Alzheimer Disease

United States
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Access Business Group
Fudan University; Sprim Advanced Life Sciences; Sinphar Pharmaceutical Co., Ltd

Completed

Effect of Ginko and Cistanche Against Fatigue Symptoms (GkoCist)

Fatigue | Mental Fatigue | Chronic Fatigue Syndrome
Reistone Biopharma Company Limited

Terminated

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Vitiligo

China
AtoGen Co. Ltd
ATOGEN AUSTRALIA PTY LTD

Recruiting

Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women

Bacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial Vaginosis

Australia
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Oblato, Inc.

Recruiting

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

Astrocytoma | Glioblastoma Multiforme | Oligodendroglioma | High-grade Glioma

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
University Hospital Marburg

Recruiting

IF-MCT 16:8: Investigating the Influence of Intermittent Fasting With and Without MCTs in Patients With Drug-resistant Epilepsy (IF-MCT16:8)

Epilepsy | Intermittent Fasting

Germany
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Azelon Pharmaceuticals

Unknown

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

Osteoporosis | Osteopenia
Aardvark Therapeutics, Inc.
Center for Psychiatry And Behavioral Medicine Inc.

Recruiting

A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

Autism Spectrum Disorder

United States
Boehringer Ingelheim

Completed

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, South Africa, Spain, Taiwan and more
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Centre Hospitalier Annecy Genevois
Hospices Civils de Lyon; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Completed

Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression (INFLUOMICS)

Vaccine Reaction

France
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia (VECTOR)

Acute Schizophrenia

Korea, Republic of, United States, Serbia, Ukraine, Romania, Poland, Canada, Latvia, Japan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Mongolian National University of Medical Sciences
Mongolian National Cancer Center

Recruiting

Interferon Alpha Therapy for Cervical CINI and HPV Infection

HPV Infection | Cervical Dysplasia

Mongolia
Boehringer Ingelheim

Completed

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

Prostatic Neoplasms
Penn State University

Withdrawn

C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation

Hereditary Angioedema
Institut Pasteur
Coalition for Epidemic Preparedness Innovations; Themis Bioscience GmbH

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101)

COVID-19

Belgium, France
Nantes University Hospital

Completed

Effect of Low Level Laser Therapy on Pain Occurring After Insertion of an Orthodontic Device (Ortholaser)

Bad Molar Teeth Arrangement Requiring Orthodontic Device

France
Boehringer Ingelheim

Completed

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Themis Bioscience GmbH

Completed

Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001) (MV-ZIKA-RSP)

Zika Virus Infection

Austria
Soovu Labs Inc.
University of Washington; Northern California Research Corporation

Completed

High Level Pulsed Heat Versus Low Level Steady Heat in Subjects With Chronic Low Back Pain

Low Back Pain | Chronic Pain | Analgesia | Heat

United States
University of Oxford
FHI 360; Oxford University Clinical Research Unit, Vietnam; Shoklo Malaria Research... and other collaborators

Completed

Targeted Chemo-elimination (TCE) of Malaria (TME)

Plasmodium Falciparum Malaria

Thailand, Cambodia, Lao People's Democratic Republic, Myanmar, Vietnam
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis (QUIDOSE)

Pulmonary Sarcoidosis
Novartis Pharmaceuticals

Completed

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Chronic Severe Plaque-type Psoriasis

Belgium, Italy, Egypt, France, Hungary, Russian Federation, Germany, Israel, Spain, Japan, Estonia, United Kingdom, Poland, Colombia, United States, Latvia, Guatemala, Romania, Switzerland
Ono Pharmaceutical Co. Ltd

Completed

Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

Austria
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Sinovac Biotech Co., Ltd

Completed

Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine

Poliomyelitis

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
Seoul National University Hospital

Active, not recruiting

Body Composition and Fatty Liver Disease

Fatty Liver

Korea, Republic of
Fudan University

Recruiting

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) (TNBC)

Breast Cancer

China
St. Francis Hospital, New York

Unknown

Plavix, Prasugrel and Drug Eluting Stents Pilot Trial (PPD)

Coronary Artery Disease | Platelet Aggregation Inhibitors | PCI- Percutaneous Coronary Intervention

United States

Search clinical trials for: Experimental: Bif-038 arm, low dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations